EPC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Edgewell Personal Care Co (EPC) is not a strong buy for a beginner, long-term investor at this time. While the stock shows some technical strength with bullish moving averages and a positive MACD, the lack of significant positive catalysts, weak financial performance, and neutral sentiment from hedge funds and insiders suggest limited upside potential. Additionally, the options data indicates bearish sentiment with a high Open Interest Put-Call Ratio of 1.81. For a long-term investor, it would be better to wait for clearer signs of growth or stronger catalysts before committing capital.
The technical indicators show a mixed picture. The MACD is positive and contracting, suggesting some bullish momentum. The RSI is neutral at 66.136, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support and resistance levels are Pivot: 21.689, R1: 22.476, S1: 20.902, R2: 22.962, S2: 20.416. However, the stock trend analysis indicates a 40% chance of a -4.06% decline in the next week, which tempers the bullish technical signals.
Bullish moving averages and positive MACD contraction. Analysts from RBC and Wells Fargo maintain Outperform and Overweight ratings, respectively, with modest price target increases.
despite YoY improvement. Gross margin dropped by 5.08% YoY. No recent news or significant trading activity from hedge funds, insiders, or Congress. Options data shows bearish sentiment with a high Open Interest Put-Call Ratio of 1.81.
In Q1 2026, revenue grew by 1.85% YoY to $422.8M, but net income remained negative at -$65.7M, albeit improving by 3028.57% YoY. EPS increased to -1.41, up 3425% YoY. Gross margin declined to 39.45%, down 5.08% YoY, indicating cost pressures.
Analysts have mixed views. RBC Capital lowered its price target to $26 from $27 but maintained an Outperform rating, citing inflationary risks and sluggish top-line growth. Wells Fargo raised its price target to $24 from $22, maintaining an Overweight rating due to improved portfolio quality. Barclays raised its target to $21 from $19 with an Equal Weight rating, noting in-line results post-divestiture.
